---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-274069"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:53:54.300960+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Verrica posts Q3 2023 net loss of $24.8M; first YCANTH revenue $2.8M

## Summary
- First commercial YCANTH sale to distributor FFF generated $2.8M product revenue; net loss $24.8M ($0.54/share).
- Non-GAAP net loss $14.8M ($0.32/share) vs. non-GAAP net income $2.9M in Q3 2022.
- SG&A surged to $20.1M (from $3.9M) due to YCANTH commercial ramp and $7.4M stock compensation.
- Over 112M lives covered by commercial/managed Medicaid; fee-for-service Medicaid in 4 states.
- Cash $84.3M; closed $125M OrbiMed debt facility ($50M drawn) to fund operations into Q1 2025.

## SEC filing metadata
- accession: 0001193125-23-274069
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312523274069/0001193125-23-274069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312523274069/d280768d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-274069
- JSON: https://secwatch.observer/filing/0001193125-23-274069.json
- Plain text: https://secwatch.observer/filing/0001193125-23-274069.txt

## Key facts
- Earnings Releases
  Verrica Pharmaceuticals Inc. reported third quarter ended September 30, 2023 results: revenue $2.8 million.
  - Period: third quarter ended September 30, 2023
  - Revenue: $2.8 million
  - Result: reported results
  source text: 24, 2023 we received our first commercial sale of YCANTH TM to our exclusive distributor, FFF Enterprises Inc., resulting in net product revenue for the third quarter 2023 of $2.8 million upon its delivery to FFF. This first sale to FFF primarily represented stocking within the channel to allow patients to finally gain access to the first FDA-approved therapy for
  evidence_url: https://www.sec.gov/Archives/edgar/data/1660334/000119312523274069/0001193125-23-274069-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.